The speaker was Gaurav Chattree, MD, movement disorder specialist at Stanford. He addressed the "phase 3" or "almost phase 3" research pipeline for disease-modification treatments and for symptomatic therapies
updates in theraupetics for Parkinson's d... - Cure Parkinson's
updates in theraupetics for Parkinson's disease
Written by
Farooqji
To view profiles and participate in discussions please or .
5 Replies
•
Thank you for posting this.
Really nothing new here. Cough syrup, exenatide... Peter Tass hit a speed bump and Dr. Chattree is down on stem cell treatment.
yes, but he has explained it in a very self explanatory way. Obviously there no major breakthrough so far on the horizon except what we already know
He has not mentioned the Japanese and Chinese stem cell trials. He has also missed Hope biosciences trial. There is much more going on on stem cell front
For me, one of Dr Chattree's "thoughts" on the stem-cell trials was an eye opener (second last slide).
"at 5 to 10 years post implantation, I suspect we will see difficult to control dyskinesias"
Wow, I had not heard that before. At least not in relation to the current stem-cell trials.
Not what you're looking for?
You may also like...
Is Parkinson's Disease an Autoimmune Disorder?
Is Parkinson's Disease an Autoimmune Disorder? https://journals.lww.com/neurotodayonline/Fulltext/20
The Endotoxin Hypothesis of Parkinson's Disease
International Parkinson and Movement Disorder Society.
Full Article:...
Parkinsons disease, base survival tactics.
its gonna get WORSE. Stash your backup meds. I watched my uncle, and grandfather and now me die...
Shining a light on Protein Aggregation in Parkinson's Disease
of the disease. Niacin is also currently being used in clinical trials in Parkinson's disease and...